Hyunsu Jung Acquires 7,000 Shares of Hyperion DeFi (NASDAQ:HYPD) Stock

Posted by George Bondi on Jun 3rd, 2026

Hyperion DeFi, Inc. (NASDAQ:HYPD – Get Free Report) insider Hyunsu Jung acquired 7,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was acquired at an average price of $3.70 per share, for a total transaction of $25,900.00. Following the completion of the purchase, the insider directly owned 1,384,676 shares of the company’s stock, valued at $5,123,301.20. This trade represents a 0.51% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Hyunsu Jung also recently made the following trade(s):

On Tuesday, June 2nd, Hyunsu Jung acquired 1,000 shares of Hyperion DeFi stock. The stock was acquired at an average price of $3.66 per share, for a total transaction of $3,660.00.

Hyperion DeFi Stock Performance

NASDAQ HYPD traded down $0.16 during trading on Tuesday, hitting $3.70. The company’s stock had a trading volume of 613,834 shares, compared to its average volume of 432,411. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 0.12. The firm has a 50 day moving average price of $3.65 and a 200 day moving average price of $3.66. The firm has a market cap of $56.08 million, a P/E ratio of -0.37 and a beta of 2.48. Hyperion DeFi, Inc. has a 52 week low of $1.71 and a 52 week high of $17.18.

Hyperion DeFi (NASDAQ:HYPD – Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($7.76) EPS for the quarter. The business had revenue of $0.50 million during the quarter. Equities research analysts forecast that Hyperion DeFi, Inc. will post 1.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Zacks Research downgraded Hyperion DeFi from a “hold” rating to a “strong sell” rating in a report on Monday, March 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Hyperion DeFi in a report on Wednesday, May 20th. Finally, Cantor Fitzgerald raised Hyperion DeFi to a “strong-buy” rating in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Hyperion DeFi currently has an average rating of “Hold” and a consensus target price of $5.88.

Read Our Latest Report on HYPD

Institutional Trading of Hyperion DeFi

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in shares of Hyperion DeFi in the 4th quarter valued at $663,000. Jane Street Group LLC acquired a new position in Hyperion DeFi in the 4th quarter worth $493,000. Focus Partners Advisor Solutions LLC bought a new position in shares of Hyperion DeFi in the 4th quarter valued at about $221,000. Geode Capital Management LLC bought a new position in shares of Hyperion DeFi in the 4th quarter valued at about $214,000. Finally, State Street Corp bought a new position in shares of Hyperion DeFi in the 4th quarter valued at about $92,000. Institutional investors own 25.84% of the company’s stock.

About Hyperion DeFi

(Get Free Report)

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.